INS and chronic obstructive pulmonary disease: Table 4 shows the hazard ratios in different subgroups of age, sex, follow-up duration, the presence or absence of diagnoses of chronic obstructive pulmonary disease (COPD)/tobacco abuse, and the use of insulin, sulfonylurea, meglitinide, acarbose, rosiglitazone, pioglitazone, angio-tensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), calcium channel blocker, statin, fibrate and aspirin.